AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan`s National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19
(WorldNews Argentina)

OCALA, FL / ACCESSWIRE / July 6, 2020/ AIM ImmunoTech (NYSE American:AIM), today announced that is has signed a material transfer and research agreement with Japan`s National Institute of Infectious Diseases (NIID) and Shionogi & Co., Ltd. (Shionogi), a leading global pharmaceutical company headquartered in Japan, in order to test AIM`s drug Ampligen as a potential adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. Under the agreement, AIM will provide Ampligen samples for various research projects. The details of all preclinical and clinical results will remain confidential until released by NIID and Shionogi. This program will be a collaboration...